1
|
Franco F, Carcereny E, Rodríguez-Abreu D, Castro RL, Cobo M, Guirado M, Massuti B, Granados AO, Mosquera J, Juan O, Blasco A, Del Barco E, Caro RB, Bosch-Barrera J, Gonzalez-Larriba J, Sala M, Pérez JT, Oramas J, Estival A, Provencio M. P52.10 Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
2
|
Calvo V, Ruano-Ravina A, Carcereny E, Moran T, Rodríguez-Abreu D, López-Castro R, Cuadrado-Albite E, Guirado M, Gomez-Gonzalez L, Massuti B, Granados AO, Blasco A, Dols MC, Mosquera J, Hernandez-Martinez A, Trigo J, Juan O, De La Rosa CA, Gómez MD, Sala M, Oramas J, Ojea CG, Cerezo S, Provencio M. P52.05 Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
3
|
Carcereny E, Franco F, Rodriguez-Abreu D, Castro RL, De Las Penas R, Guirado M, Camps C, Bosch-Barrera J, Campelo RG, Ortega A, Gonzalez-Larriba J, Huidobro G, Domine M, Massuti B, Sala M, Bernabe R, Oramas J, Del Barco E, De Castro Carpeno J, Padilla A, Aguiar D, Cerezo S, Blanco R, Albite EC, Benitez G, Domenech M, Provencio M. P2.10-02 Smoking Habit in Lung Cancer in Spain. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
4
|
Rodriguez-Abreu D, Moran T, Castro RL, Guirado M, Camps C, Nunez B, Bosch-Barrera J, Bernabe R, Lazaro M, Campelo RG, Larriba JG, Massuti B, Ortega A, Domine M, Sala M, Padilla A, Del Barco E, Oramas J, Blanco R, Estival A, Benitez G, Provencio M. P2.05-12 Analysis of Biomarkers in Lung Cancer in Spain. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Rittmeyer A, Chouaid C, Kim J, Ahn M, Gorbunova V, Scherpereel A, Oramas J, Walzer S, Barlesi F. 9076 POSTER An Interim Analysis of Health-Related Quality of Life (HRQoL) in Patients With Non-Squamous Non-Small-Cell Lung Cancer (nsNSCLC) Receiving Bevacizumab Vs Bevacizumab+Pemetrexed for Maintenance Therapy in AVAPERL 1. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72388-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Oramas J, Cobo M, Paredes A, Arriola E, Sala M, Artal A, Girones R, Martinez M, Figueroa S, Domine M. 9075 POSTER ARIADNA Study – Evaluation of Symptoms on Daily Life and Health-related Quality of Life (HRQoL) of Patients With Advanced Non-small Cell Lung Cancer (NSCLC). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72387-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
7
|
Provencio M, Cobo M, Vazquez-Estevez S, Firvida J, Maciá S, Barneto I, Oramas J, Sanchez-Hernandez A, Ferrer N, Paredes A. Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Maestu I, Isla D, Pedraza M, Munoz J, Oramas J, Garcia-Gomez R, del Barco S, Cantos B, Taron M, Rosell R. 6588 POSTER Vinorelbine (VRL) plus gemcitabine (GEM) as first-line treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC): molecular correlates. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71416-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
9
|
Alberola V, Gallego O, López-Vivanco G, Mesía C, Oramas J, Trigo JM, Virizuela JA, Camps C, Regueiro P, Massutí B. Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18140 Background: Erlotinib is an EGFR TKI that is effective in the treatment of advanced NSCLC, in terms of longer survival, better quality of life and delayed symptom progression.We present here the outcome of a group of p from the TargeT study, whose QoL was assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire and the Lung Cancer Subscale (LCS). Methods: TargeT study was a multicenter, single-arm phase II study evaluating efficacy, safety, and tolerability of erlotinib (150 m/day) in p with stage IIIB or IV NSCLC, in 1st, 2nd and 3rd line treatment. Primary end-point was time to progression. QoL was a secondary end point as assessed monthly by the Functional Assessment of Cancer Therapy-Lung questionnaire (FACT- L) and its Lung Cancer Subscale. Physical and functional aspects of the QoL were measured by the Trial Outcome Index (TOI), which is the sum of the physical well being, functional well-being and LCS scores from the FACT-L questionnaire. Results: Data from 91 pts were available. QoL analysis showed that 53% of the p (95% IC 37–58%) had improvement in FACT-L or TOI. Similarly, 45% (95% IC35–56%) of improved their symptoms from baseline. Improvement was observed for each individual LCS item and specifically in the pulmonary items. In symptomatic p, shortened of breath was 17,6% at baseline vs 2.2% after treatment (p<0.001) and cough was 24.7% vs 8.8 % (p<0.001) after treatment. Those improvements in symptoms were rapid and, 73% of the patients who improved showed that recovery in the first cycle of treatment. In terms of association between efficacy of erlotinib and QoL, there is a statistically significative relationship between objective response and improvement in TOI or FACT-L (p<0.02). Conclusions: This QoL analysis confirms that erlotinib improves both symptoms and functional aspect of patients with NSCLC. The improvement in QoL is related with objective response. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Alberola
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - O. Gallego
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - G. López-Vivanco
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - C. Mesía
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - J. Oramas
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - J. M. Trigo
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - J. A. Virizuela
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - C. Camps
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - P. Regueiro
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - B. Massutí
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| |
Collapse
|
10
|
Maestu I, Isla D, Diz P, Muñoz J, Oramas J, Garcia R, del Barco S, Provencio M, Taron M, Rosell R. Vinorelbine (VRB) plus gemcitabine (GEM) as first-line treatment for elderly patients (p) with advanced non-small cell lung cancer (NSCLC): Molecular correlates. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18040 Background: The clinical benefit of non-cisplatin doublets vs a single agent in elderly or unfit p is still controversial. The present study focuses on clinical outcome with VRB/GEM in elderly p and the role of functional status and comorbidities. Genetic predictive markers of response to VRB/GEM will also be examined in genomic and cDNA from tumor and circulating tumor DNA. Methods: 145 chemonaive p with stage IIIB (pleural effusion or supraclavicular lymph nodes)-IV or recurrent NSCLC and age > 70 years were accrued at 32 sites between April 2004 and January 2006. Treatment consisted of VRB 25 mg/m2 IV or 60–80 mg/m2 oral plus GEM 1200 mg/m2, days 1, 8 every 21 days. Activities of daily living (ADL), instrumental activities of daily living (IADL) and comorbidities were evaluated. DNA samples were collected from primary tumors for the assessment of microtubule associated protein 4 (MAP4) and from serum for the checkpoint with forkhead-associated and ring finger (CHFR) methylation. Results: Data on 130 p is available. Median age 76 years (69–83); males: 86.8%; smokers: 70.5%; PS 0–1: 83.9%; adenocarcinoma: 34.4% / squamous: 48%; stage IIIB: 22.7%, IV: 77.3%. Self-sufficiency in ADL and IADL was 77.4% and 45.2% of the p analyzed. 68% of the p had comorbidities. Median cycles: 3 (1–8). Hematological toxicities (%p): grade 3/4 neutropenia, 7.8%/4.7%; grade 3/4 thrombocytopenia, 2.3%/0.8%; grade 3 anemia, 3.1%. Efficacy in evaluable population: PR, 23.2% (95% CI, 15.1% to 32.9%); SD, 41.1%. 24 p died during the treatment period (non toxicity related) and 21 p were not evaluable. With a median follow up of 5.8 months, median survival for the whole population was 4.97 months (m), progression free survival 4.53 m, event free survival 3.43 m, 1-year survival 26.6%. Statistically significant differences in median survival were observed among subgroups: PS 0–1/2, 6.5/2.3 m (p<0.001); sex male/female, 4.5/9.7 m (p 0.027); ADL <6/=6, 3.4/7.1 m (p 0.023). Conclusions: This trial confirms that VRB/GEM is effective, presenting a favorable toxicity profile in elderly p with advanced NSCLC. Complete data on genetic markers will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Maestu
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - D. Isla
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - P. Diz
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - J. Muñoz
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - J. Oramas
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - R. Garcia
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - S. del Barco
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - M. Provencio
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - M. Taron
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| | - R. Rosell
- Hospital Virgen de los Lirios, Alcoy, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario de León, León, Spain; Hospital Universitario Dr Peset, Valencia, Spain; Hospital Universitario de Tenerife, La Laguna, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Josep Trueta, Girona, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Germans Trias i Pujol, Badalona, Spain
| |
Collapse
|
11
|
Alonso B, Aleman R, Rodríguez L, Llanos M, Cruz J, Oramas J, Rodríguez E, García R, Ponce S, Batista J. Bone mineral density in women with non-metastatic breast cancer: Effect of intravenous bisphosphonates given before adjuvant therapies. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11038 Background: Adjuvant therapies shown survival improve of non-metastatic breast cancer (NMBC) patients, but they also decrease bone mineral density (BMD). Bisphosphonates are effective agents for the management of osteoporosis. Intravenous zoledronate, which is approved for the treatment of malignant hypercalcemia, multiple myeloma, and skeletal metastases, can suppress bone resorption and are often considered first-line therapy for the treatment of osteoporosis. We have analyzed the effects of chemotherapy on BMD of women with NMBC who received before adjuvant therapies intravenous bisphosphonates (zoledronic acid). Methods: We prospectively studied the effects of a single intravenous zoledronic acid dose (4 mg), on BMD of 74 women with NMBC (stage I-III), administred previous to the adjuvant therapies. The patients were referred to the Medical Oncology Service of University Hospital of Canary Islands between 2003 y 2006. Lumbar and hip BMD (g/cm2) was measured at diagnosis and after chemotherapy. The results were compared with a group of 80 patients with NMBC who received adjuvant therapy without intravenous bisphosphonates. Results: Breast cancer patients the median age was 52 ± 10 years old and the body mass index was 28,2 ± 5.5 kg/m2. At baseline there were not differences in BMD between the group that received bisphosphonates and the group with only chemotherapy at any of lumbar or femoral bone sites. In our study, the BMD after chemotherapy and intravenous bisphosphonates (n=74) significantly increased at femoral neck (0.805 ± 0.01, 0,826± 0.12; p=0.002) and trochanter (0.709 ± 0.01, 0.724 ± 0.01; p=0.002) and remained stable at lumbar, intertrochanter, total hip and Ward’s triangle; whether the group without bisphosphonates significantly decreased at lumbar (1.014 ± 0; 0.995 ± 0, p=0.0001), trochanter (0.701± 0; 0.690 ± 0, p=0,046), intertrochanter (1,095 ± 0; 1.078 ± 0, p=0.0001) and total hip (0,924 ± 0; 0.915 ± 0, p=0.046) areas (table). Conclusions: Women with NMBC are affected by early bone loss after adjuvant chemotherapy. Bisphosphonates intravenous (zoledronic acid) given before adjuvant therapy might be an effective treatment for this bone loss, increasing BMD or remaining stable. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Alonso
- Hospital Universitario de Canarias, La Laguna, Spain
| | - R. Aleman
- Hospital Universitario de Canarias, La Laguna, Spain
| | - L. Rodríguez
- Hospital Universitario de Canarias, La Laguna, Spain
| | - M. Llanos
- Hospital Universitario de Canarias, La Laguna, Spain
| | - J. Cruz
- Hospital Universitario de Canarias, La Laguna, Spain
| | - J. Oramas
- Hospital Universitario de Canarias, La Laguna, Spain
| | - E. Rodríguez
- Hospital Universitario de Canarias, La Laguna, Spain
| | - R. García
- Hospital Universitario de Canarias, La Laguna, Spain
| | - S. Ponce
- Hospital Universitario de Canarias, La Laguna, Spain
| | - J. Batista
- Hospital Universitario de Canarias, La Laguna, Spain
| |
Collapse
|
12
|
Batista N, Estevez L, Sánchez-Rovira P, Velasco A, Dómine M, Lobo F, Oramas J, Cruz J. Phase II study of capecitabine (X) in combination with vinorelbine (N) in patients (pts) with pretreated metastatic breast cancer (MBC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10693 Background: X monotherapy is consistently effective and very well tolerated in pretreated MBC. N is also commonly used in this indication. In several studies, the combination of X + N led to response rates ranging from 43–67% in first-line MBC. As there are few data on the combination in pts with pretreated MBC, we evaluated the efficacy and safety of X + N in a multicenter phase II trial of pts previously treated with anthracycline- and taxane-containing regimens. Methods: Women >18 years of age with pretreated MBC, PS 0–2 and adequate organ function were enrolled to receive a 3-weekly regimen of XN: X 1000mg/m2 twice daily on days 1–14 and N 25mg/m2 on days 1&8, every 3 weeks up to a maximum of 6 cycles, disease progression or unacceptable toxicities. Results: A total of 32 pts were enrolled, median age 58 years (range 41–77), PS 0(74%), 1(19%), postmenopausal (61%). The most frequent sites of metastases were: liver (68%), nodes (36%), lung (36%). 58% of pts had ≥2 metastatic sites. 27 patients (87%) previously failed on anthracycline and taxane chemotherapy regimens. 152 cycles were administered with a median of 3 cycles/pt (range 1–10). Median relative dose intensity was 0.86 (0.51–1.01] for N and 0.85 (0.26–1.03] for X. All pts were evaluable for safety. The most common grade 3/4 clinical adverse events were vomiting (15%), asthenia (9%), and hand-foot syndrome (6%). Grade 3/4 hematological toxicities were: neutropenia (47%), leucopenia (9%), thrombocytopenia (3%). One pt died due to septic shock after the first cycle. 29 pts are evaluable for efficacy: the overall response rate was 52% (4 CR, 11 PR), with stable disease in 8 pts (28%). Median TTP was 7.5 months [95% CI, 5.7–9.8]. Conclusions: Our preliminary data indicate that the combination of X and N has promising clinical activity and good safety in pts with MBC who have failed prior taxane- and anthracycline-containing regimens. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Batista
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - L. Estevez
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - P. Sánchez-Rovira
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - A. Velasco
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - M. Dómine
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - F. Lobo
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - J. Oramas
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - J. Cruz
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| |
Collapse
|
13
|
Estevez LG, Batista N, Sánchez-Rovira P, Velasco A, Domine M, Lobo F, Oramas J, Cruz J. Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.748] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. G. Estevez
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - N. Batista
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - P. Sánchez-Rovira
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - A. Velasco
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - M. Domine
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - F. Lobo
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - J. Oramas
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - J. Cruz
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| |
Collapse
|
14
|
Llanos M, Alvarez-Argüelles H, Alemán R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2002; 18:15-22. [PMID: 11778965 DOI: 10.1385/mo:18:1:15] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
We analyzed 104 patients with non-Hodgkin's lymphoma, follicular or diffuse large-B-cell-type lymphoma, in order to evaluate the correlation between clinical characteristics and immunohistochemical parameters. Immunostaining was performed by means of monoclonal antibodies against Ki-67, bcl-2, and p53 expression. Forty-nine of the patients showed follicular lymphoma. A high expression of bcl-2 was found in 93%, high expression of p53 in 57%, and low expression of Ki-67 in 96%. Follicular lymphoma grade III showed a p53 expression (p = 0.07) slightly higher than follicular lymphoma grades I and II, not reaching statistical significance. Follicular lymphoma grades I and II tended to express lower Ki-67 and higher levels of bcl-2 expression than grade III (p = 0.06). Fifty-five cases showed diffuse large-B-cell lymphoma. Among them, bcl-2 was absent in 39%, whereas p53 and Ki-67 expression were high in 38%. In the diffuse large-B-cell lymphomas, a high bcl-2 expression correlated with stages III and IV (p = 0.03) and involvement of more than one extranodal area (p = 0.03). High Ki-67 expression was also associated to extranodal involvement of more than one area (p = 0.03). Overall survival of patients did not show statistically significant differences regarding Ki-67, bcl-2, and p53 tumoral expression. Prognostic factors for overall survival in the multivariate analysis were age (p = 0.02) and LDH (p = 0.003). Time to progression was worse among follicular lymphoma with high p53 expression than with mild/moderate p53 expression (p = 0.009).
Collapse
Affiliation(s)
- M Llanos
- Department of Medical Oncology, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain.
| | | | | | | | | | | |
Collapse
|
15
|
Martín F, Santolaria F, Batista N, Milena A, González-Reimers E, Brito MJ, Oramas J. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80-6. [PMID: 10080883 DOI: 10.1006/cyto.1998.0398] [Citation(s) in RCA: 158] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Raised serum levels of interleukin 6 (IL-6) have been described in cancer patients. This cytokine mediates the acute phase response and has been also involved in the pathogenesis of cancer cachexia. The objectives of the present study were: (1) to determine the relationships of IL-6 and other cytokines with neoplasia extension, acute phase response and nutritional status, in lung cancer patients; and (2) to establish the prognostic value of serum cytokine levels. A prospective study in which IL-1, IL-2, IL-6, tumour necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) have been determined in 66 newly diagnosed lung cancer patients. Nutritional status was assessed objectively. Serum levels of growth hormone (GH), insulin growth factor 1 (IGF-1) and acute phase reactants as C Reactive Protein, alpha1 antitrypsin and ferritine, were determined. Increased IL-6 levels were related to extensive disease, impaired performance status, enhanced acute phase response and malnutrition. Raised serum IL-6 levels, extensive disease, low Karnofsky index, malnutrition, acute phase response and low IFN-gamma were all related to a shorter survival. When assessed by a multivariate analysis, IL-6 kept its independent prognostic value together with age, disease extension, and decreased IFN-gamma serum levels.IL-6 is increased in lung cancer patients, enhances the acute phase response in them, and is correlated with poor nutritional status, impaired performance status and shorter survival.
Collapse
Affiliation(s)
- F Martín
- Servicio de Medicina Interna, Sección de Oncología Médica, Hospital Universitario de Canarias, Tenerife, Spain
| | | | | | | | | | | | | |
Collapse
|